Table 3.

Univariate and multivariate Cox proportional hazard analysis of LYNX1 expression and overall survival (OS) for patients with ovarian serous cystadenocarcinoma (OVs) in the validation cohort.

Characteristics	HR (95% CI) univariate analysis	p value univariate analysis	HR (95% CI) multivariate analysis	p value multivariate analysis
Clinical stage (stage I/II vs. stage III/IV)	2.085 (0.925–4.699)	0.076	2.328 (0.567–9.55)	0.241
Primary therapy outcome (SD-PD vs. PR-CR)	0.303 (0.205–0.447)	<0.001	0.336 (0.218–0.516)	<0.001
Cancer status (tumor free vs. with tumor)	8.466 (4.591–15.611)	<0.001	11.874 (4.798–29.383)	<0.001
Histologic grade (G1G2 vs. G3G4)	1.194 (0.797–1.789)	0.389
Tumor residual disease (NRD vs. RD)	2.302 (1.479–3.583)	<0.001	1.094 (0.653–1.834)	0.734
Anatomic neoplasm subdivision (unilateral vs. bilateral)	1.041 (0.768–1.41)	0.798
Age (<60 vs. ≥60)	1.329 (1.025–1.722)	0.032	1.384 (1.001–1.915)	0.049
LYNX1 (low vs. high)	1.414 (1.089–1.837)	0.009	1.698 (1.22–2.363)	0.002

SD: stable disease; PD: progressive disease; PR: partial remission; CR: complete remission; NRD: no residual disease; RD: residual disease; HR: hazard ratio; CI: confidence interval.